NCT02646826View on ClinicalTrials.gov

Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

November 30, 2017

Conditions
Nocturia
Interventions
OTHER

Placebo

Subjects are treated with Placebo tablets

DRUG

Paxerol - Dose Level 1

Subjects are treated with the first dose level of Paxerol

DRUG

Paxerol - Dose Level 2

Subjects are treated with the second dose level of Paxerol

DRUG

Paxerol - Dose Level 3

Subjects are treated with the third dose level of Paxerol

Trial Locations (4)

10021

Dr. George Klein, New York

10032

Washington High Urology, New York

10604

The Westchester Medical Group PC, Harrison

11229

A and I Medical P.C., Brooklyn

All Listed Sponsors
lead

Wellesley Pharmaceuticals, LLC

INDUSTRY

NCT02646826 - Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial | Biotech Hunter | Biotech Hunter